Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)

Secondary Objectives:

To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi

Criteria

Inclusion criteria :

• 18 to 55 years of age inclusive

• Diagnosis of PPMS according to the 2017 McDonald criteria

• Expanded disability status scale (EDSS) between 2.0 to 6.5 points, inclusive at screening

• Disease duration from the onset of MS symptoms of <15 years if screening EDSS score of >5.0 OR <10 years if screening EDSS score of ≤5.0.

• Positive cerebrospinal fluid oligoclonal bands and/or elevated Immunoglobulin G (IgG) index either during screening or documented previous history.

• Contraceptive use consistent with local regulations for individuals participating in clinical studies

• Participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

• Is not a woman of child bearing potential (WOCBP) OR

• Is a WOCBP and agrees to use an acceptable contraceptive method

Exclusion criteria:

• Participant has conditions that would adversely affect study participation such as short life expectancy.

• History of organ transplant.

• Evidence of infection with human immunodeficiency virus (HIV), progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation.

• History of malignancy within 5 years prior to screening.

• History of alcohol or drug abuse within 1 year prior to Screening.

• Hospitalized for psychiatric disease within 2 years prior to Screening.

• Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening.

• Bleeding disorder, known platelet dysfunction or platelet count <150 000/μL at Screening.

• Lymphocyte count below the lower limit of normal at Screening.

• Recent live (attenuated) vaccine within 2 months before the first treatment visit.

• Recent major surgery (within 4 weeks of Screening) or planned major surgery during the study.

• The participant has received medications/treatments for MS within a specified time frame.

• Receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes.

• Receiving anticoagulant or antiplatelet therapy (such as aspirin, clopidogrel, warfarin).

• Contraindications to magnetic resonance imaging (MRI).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.